Inventor
Noah Bell
Inventor
Berkeley, CA, US
Overview
Patents· 16 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
C07DHeterocyclic compounds24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
Y02ATechnologies for adaptation to climate change10%
C07CAcyclic or carbocyclic compounds8%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium8%
C07BGeneral methods of organic chemistry2%
C07HSugars2%
PatentTitleYear
10,543,207Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders202010,392,413Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists201910,385,024Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders201910,376,481Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders20199,408,840'Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder'20169,301,951'Compounds and methods for inhibiting phosphate transport'20169,289,429'Compounds and methods for inhibiting phosphate transport'20169,289,430'Compounds and methods for inhibiting phosphate transport'20169,278,102'Compounds and methods for inhibiting phosphate transport'20169,006,281'Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders'20158,969,377'Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders'20158,916,569'Compounds and methods for inhibiting phosphate transport'20148,815,910'Compounds and methods for inhibiting phosphate transport'20148,815,908'Compounds and methods for inhibiting phosphate transport'20148,809,339'Compounds and methods for inhibiting phosphate transport'20148,541,448'Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders'2013Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2013–2020Patents assigned to ARDELYX INC (16)· patent assignee history
2013Patents assigned to BELL NOAH (1)· patent assignee history
2013Patents assigned to CARRERAS CHRISTOPHER (1)· patent assignee history
2013Patents assigned to CHARMOT DOMINIQUE (1)· patent assignee history
2013Patents assigned to JACOBS JEFFREY W (1)· patent assignee history
2013–2020Based in Berkeley, CA, US· patent location history
2015–2019Based in Fremont, CA, US· patent location history
2019Based in Los Angeles, CA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ARDELYX INC | 16 | 2013–2020 |
| BELL NOAHself | 1 | 2013 |
| CARRERAS CHRISTOPHER | 1 | 2013 |
| CHARMOT DOMINIQUE | 1 | 2013 |
| JACOBS JEFFREY W | 1 | 2013 |
Locations
| Location | Patents | Span |
|---|---|---|
| Berkeley, California, US | 11 | 2013–2020 |
| Fremont, California, US | 4 | 2015–2019 |
| Los Angeles, California, US | 1 | 2019 |